On February 17, 2026, Integral Health Asset Management disclosed a buy of 100,000 Vera Therapeutics (NASDAQ:VERA) shares, an estimated $3.55 million trade based on quarterly average pricing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Integral Health Asset Management increased its position in Vera Therapeutics by 100,000 shares. The estimated value of this trade, based on the average closing price for the quarter ending December 31, 2025, is $3.55 million. The quarter-end value of the position rose by $41.75 million, reflecting share purchases and changes in the stock price.

The fund’s buy brings its Vera Therapeutics stake to 4.53% of 13F assets under management.

Top holdings after the filing:

NASDAQ:INSM: $217.55 million (11.0% of AUM)

NASDAQ:RVMD: $95.58 million (4.8% of AUM)

NASDAQ:VERA: $91.15 million (4.5% of AUM)

NASDAQ:CYTK: $88.96 million (4.5% of AUM)

NASDAQ:REGN: $81.05 million (4.1% of AUM)

As of Friday, shares of Vera Therapeutics were priced at $40.93, up 48% over the past year and well outperforming the S&P 500’s roughly 16% gain in the same period.

Metric

Value

Market Capitalization

$2.9 billion

Price (as of Friday)

$40.93

Net Income (TTM)

($299.6 million)

VERA focuses on developing and commercializing treatments for serious immunological diseases, with lead product candidates including atacicept for immunoglobulin A nephropathy and MAU868 for BK viremia infections.

The firm operates as a clinical-stage biotechnology company focused on the advancement and potential commercialization of proprietary biologic therapies, but has not yet generated revenue.

It targets patients with serious immunological diseases in the United States.

Vera Therapeutics, Inc. is a biotechnology company specializing in innovative therapies for immunological and kidney-related diseases. The company leverages advanced biologic platforms to address significant gaps in treatment for complex patient populations. Its strategic focus on late-stage clinical development and targeted indications positions it for potential leadership in the immunology therapeutics market.

Vera is at a critical moment. The company’s lead drug, atacicept, has already delivered positive Phase 3 data in IgA nephropathy and now faces a July 7 FDA decision, with a potential U.S. launch expected shortly after.

Financially, the picture is what you want heading into that catalyst. Vera ended 2025 with about $714.6 million in cash and investments, supported by financing efforts that could bring total proceeds to roughly $800 million, giving it runway through commercialization and beyond. Still, losses widened to about $299.6 million last year, but that seemingly reflects late-stage trial and launch prep spending rather than deterioration in the underlying thesis.

Within a portfolio already concentrated in biotech names like Insmed and Revolution Medicines, this position fits the pattern of high-conviction bets around defined clinical catalysts. If commercialization moves on as hoped for and it gains traction, this type of move makes perfect sense.

Before you buy stock in Vera Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vera Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $494,747!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,094,668!*

Now, it’s worth noting Stock Advisor’s total average return is 911% — a market-crushing outperformance compared to 186% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of March 20, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cytokinetics and Regeneron Pharmaceuticals. The Motley Fool has a disclosure policy.

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year was originally published by The Motley Fool